| Type of support |
Approvals 2001-2023 (US$)(17 Sep 2019) |
Commitments 2001-2023 (US$)(17 Sep 2019) |
Disbursements 2000-2019 (US$)(17 Sep 2019) |
% Disbursed(17 Sep 2019) |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
|---|
|
| Total |
$244,878,557 |
$250,227,044 |
$259,723,474 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash Support (CASHSUPP) |
$170,000 |
$170,000 |
$170,000 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cold Chain Equipment Optimisation Platform (CCEOP) |
$4,577,948 |
$5,128,062 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 1) |
$24,392,121 |
$29,190,494 |
$22,373,683 |
92% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV Demo (NVS) |
$56,503 |
$56,503 |
$56,503 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Immunisation services support (ISS) |
$1,665,500 |
$1,665,500 |
$1,665,500 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Injection Safety Devices (NVS) |
$1,925,969 |
$1,925,969 |
$2,163,506 |
112% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Injection safety support (INS) |
$835,881 |
$835,881 |
$835,881 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IPV (NVS) |
$9,911,927 |
$9,911,927 |
$9,916,278 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles (NVS) |
$1,077,756 |
$1,077,756 |
$1,077,756 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MR 1st and 2nd dose (NVS) |
$566,000 |
$566,000 |
$582,064 |
103% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MR 1st dose (NVS) |
$721,500 |
$721,500 |
$730,295 |
101% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MR-Catch-up campaign (NVS) |
$9,499,000 |
$9,499,000 |
$9,742,824 |
103% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MR-Catch-up campaign op.costs (OPC) |
$7,935,500 |
$7,935,500 |
$7,879,866 |
99% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Penta (NVS) |
$47,512,655 |
$47,512,655 |
$47,728,722 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pneumo (NVS) |
$94,938,411 |
$94,938,411 |
$116,465,686 |
123% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Product Switch Grant (PSG) |
$292,000 |
$292,000 |
$271,286 |
93% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rotavirus (NVS) |
$19,852,174 |
$19,852,174 |
$19,115,912 |
96% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tetra DTP-HepB (NVS) |
$16,897,320 |
$16,897,320 |
$16,897,320 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vaccine Introduction Grant (VIG) |
$2,050,392 |
$2,050,392 |
$2,050,392 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding
Download data for commitments, approvals & disbursements in XLS format